Persistent inflammation worsens short-term outcomes in massive stroke patients

BackgroundPersistent inflammation is an important driver of disease progression and affects prognosis. Some indicators of inflammation predict short-term outcomes. The relationship between prognosis, especially mortality, and persistent inflammation in massive stroke has not been studied, and this has been the subject of our research.MethodsFrom April 1, 2017 to February 1, 2020, consecutive patients were prospectively enrolled. Clinical data, laboratory data, imaging data and follow-up infections morbidity were compared between 2 groups according to modified Rankin scale (mRS) scores (mRS<3 and<greater than or equal to>3) at 1 month. The binomial logistic analysis was used to determine independent factors of 1-month prognosis. Short-term functional outcome, mortality and infection rates in massive stroke with and without persistent inflammation were compared.ResultsOne hundred thirty-nine patients with massive stroke were included from 800 patients. We found that admission blood glucose levels (p=0.005), proportions of cerebral hemispheric (p=0.001), posterior circulatory (p=0.035), and lacunar (p=0.022) ischemia were higher in poor outcome patients; neutrophil-to-lymphocyte ratio (odd ratio=1.87, 95%CI 1.14-3.07, p=0.013) and blood glucose concentrations (odd ratio=1.34, 95%CI 1.01-1.79, p=0.043) can independently predict the short-term prognosis in massive stroke patients. We also found that the incidence of pulmonary infection (p=0.009), one-month mortality (p=0.003) and adverse outcomes (p=0.0005) were higher in patients with persistent inflammation.ConclusionsThis study suggested that persistent inflammation is associated with poor prognosis, 1-month mortality and the occurrence of in-hospital pulmonary infection and that higher baseline inflammation level predicts short-term poor outcomes in massive stroke.